PL3733712T3 - Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu - Google Patents

Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu

Info

Publication number
PL3733712T3
PL3733712T3 PL20180938.1T PL20180938T PL3733712T3 PL 3733712 T3 PL3733712 T3 PL 3733712T3 PL 20180938 T PL20180938 T PL 20180938T PL 3733712 T3 PL3733712 T3 PL 3733712T3
Authority
PL
Poland
Prior art keywords
ofatumumab
methods
multiple sclerosis
treating multiple
treatment schedules
Prior art date
Application number
PL20180938.1T
Other languages
English (en)
Inventor
Erik WALLSTRÖM
Marina SAVELIEVA PRAZ
Algirdas Jonas KAKARIEKA WEISSKOPF
Joseph Michael KAHN
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3733712T3 publication Critical patent/PL3733712T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PL20180938.1T 2016-08-15 2017-08-11 Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu PL3733712T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662374986P 2016-08-15 2016-08-15

Publications (1)

Publication Number Publication Date
PL3733712T3 true PL3733712T3 (pl) 2023-10-16

Family

ID=59901554

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17768863T PL3497132T3 (pl) 2016-08-15 2017-08-11 Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu
PL20180938.1T PL3733712T3 (pl) 2016-08-15 2017-08-11 Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17768863T PL3497132T3 (pl) 2016-08-15 2017-08-11 Schematy i sposoby leczenia stwardnienia rozsianego z zastosowaniem ofatumumabu

Country Status (24)

Country Link
US (5) US11161909B2 (pl)
EP (5) EP3497132B1 (pl)
JP (2) JP6851391B2 (pl)
KR (2) KR20200136503A (pl)
CN (5) CN120000782A (pl)
AU (2) AU2017311664C1 (pl)
CA (2) CA3030530C (pl)
CY (1) CY1123350T1 (pl)
DE (1) DE202017007542U1 (pl)
DK (2) DK3733712T3 (pl)
ES (2) ES2954259T3 (pl)
FI (1) FI3733712T3 (pl)
HR (2) HRP20230894T1 (pl)
HU (2) HUE063625T2 (pl)
IL (4) IL302488B2 (pl)
LT (2) LT3733712T (pl)
MX (1) MX388593B (pl)
PL (2) PL3497132T3 (pl)
PT (2) PT3733712T (pl)
RS (2) RS60807B1 (pl)
RU (1) RU2749951C2 (pl)
SI (2) SI3497132T1 (pl)
TW (1) TWI752995B (pl)
WO (1) WO2018033841A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
MX2022003010A (es) * 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
EP4707302A2 (en) * 2020-04-09 2026-03-11 Novartis AG Ofatumumab for treating ms while maintaining serum igg
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4816401A (en) 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US20020064823A1 (en) 2000-03-30 2002-05-30 Welcher Andrew A. CD20/IgE-receptor like molecules and uses thereof
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2012018704A1 (en) 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
EP2663331A4 (en) * 2011-01-10 2015-07-15 Glaxosmithkline Intellectual Property Man Ltd NEW USES
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
SG11201500499TA (en) 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
JP2018506275A (ja) * 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CN106699886A (zh) 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
US20220389109A1 (en) 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
MX2022003010A (es) 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
EP4707302A2 (en) 2020-04-09 2026-03-11 Novartis AG Ofatumumab for treating ms while maintaining serum igg
WO2022219057A1 (en) 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients
US20240343821A1 (en) 2021-08-16 2024-10-17 Novartis Ag Ofatumumab for treating pediatric ms

Also Published As

Publication number Publication date
JP6851391B2 (ja) 2021-03-31
IL302488B1 (en) 2024-08-01
KR20200136503A (ko) 2020-12-07
PT3497132T (pt) 2020-09-25
US12570754B2 (en) 2026-03-10
US20220081488A1 (en) 2022-03-17
RS60807B1 (sr) 2020-10-30
CN120053639A (zh) 2025-05-30
US20240150485A1 (en) 2024-05-09
MX388593B (es) 2025-03-20
US20240317878A1 (en) 2024-09-26
JP2020100630A (ja) 2020-07-02
IL264804B (en) 2020-09-30
CN120037367A (zh) 2025-05-27
MX2019001860A (es) 2019-07-08
AU2017311664A1 (en) 2019-01-31
IL276890A (en) 2020-10-29
PT3733712T (pt) 2023-08-31
AU2020201112B2 (en) 2021-07-22
EP4252847A3 (en) 2023-11-15
DK3733712T3 (da) 2023-08-21
DK3497132T3 (da) 2020-09-07
AU2017311664B2 (en) 2020-01-02
HUE051948T2 (hu) 2021-03-29
EP4711008A2 (en) 2026-03-18
AU2020201112C1 (en) 2025-05-22
HRP20201388T1 (hr) 2020-11-27
ES2954259T3 (es) 2023-11-21
EP3733712A1 (en) 2020-11-04
PL3497132T3 (pl) 2020-11-30
CN109641965A (zh) 2019-04-16
AU2020201112A1 (en) 2020-03-05
JP2019511506A (ja) 2019-04-25
HRP20230894T1 (hr) 2023-11-24
SI3497132T1 (sl) 2020-10-30
WO2018033841A1 (en) 2018-02-22
AU2017311664C1 (en) 2025-05-22
TWI752995B (zh) 2022-01-21
CA3101514A1 (en) 2018-02-22
IL276890B2 (en) 2023-10-01
IL302488A (en) 2023-06-01
EP4371611A2 (en) 2024-05-22
EP3733712B1 (en) 2023-05-24
IL302488B2 (en) 2024-12-01
CN120000782A (zh) 2025-05-16
ES2821924T3 (es) 2021-04-28
HUE063625T2 (hu) 2024-01-28
IL276890B1 (en) 2023-06-01
RS64541B1 (sr) 2023-09-29
CY1123350T1 (el) 2021-12-31
FI3733712T3 (fi) 2023-08-22
CN120053638A (zh) 2025-05-30
TW201808333A (zh) 2018-03-16
RU2019107146A (ru) 2020-09-15
LT3497132T (lt) 2020-10-12
US20190177424A1 (en) 2019-06-13
RU2019107146A3 (pl) 2020-09-15
LT3733712T (lt) 2023-09-11
RU2021105514A (ru) 2021-04-19
DE202017007542U1 (de) 2022-07-19
US12338290B2 (en) 2025-06-24
SI3733712T1 (sl) 2023-12-29
EP4252847A2 (en) 2023-10-04
CA3030530C (en) 2021-02-23
EP4371611A3 (en) 2024-07-24
IL313932A (en) 2024-08-01
US11161909B2 (en) 2021-11-02
JP7198786B2 (ja) 2023-01-04
EP3497132A1 (en) 2019-06-19
CA3030530A1 (en) 2018-02-22
EP3497132B1 (en) 2020-06-24
RU2749951C2 (ru) 2021-06-21
US20250289902A1 (en) 2025-09-18
RU2021105514A3 (pl) 2022-02-08
KR20190038914A (ko) 2019-04-09

Similar Documents

Publication Publication Date Title
EP3554401A4 (en) EYE TREATMENT DEVICES AND ASSOCIATED PROCEDURES FOR USE
IL257663B (en) Oral care compositions and methods of use
PL3402888T3 (pl) Środki i sposoby leczenia hbv
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
EP3681479A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
PT3142637T (pt) Formulações e métodos de tratamento de queratina
EP3458158A4 (en) COMPOSITIONS AND METHODS FOR TREATING ECZEMA
EP3458099A4 (en) COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF VULGAR ACNE
EP3484526A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASE
EP3655534C0 (en) COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES
EP3541408C0 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS
EP3871664C0 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES OR DISORDERS USING SUSTAINED RELEASE NITRIC OXIDE SOLUTIONS
EP3436157C0 (en) METHOD AND COMPOSITION FOR TREATING SKIN PROBLEMS
EP3741747C0 (en) METHOD FOR PREVENTION AND/OR TREATMENT OF ANXIETY
EP3139928C0 (en) ANORDRINE COMPOSITIONS AND METHODS OF TREATING DISEASES
SG11201607881SA (en) Methods of treating nail and scalp psoriasis
IL276890A (en) Dosing regimens and methods for the treatment of multiple sclerosis using opatumumab
EP3719032A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF HAIR LOSS
EP3291776C0 (en) PEN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS AND METHOD OF USE THEREOF
EP3522873A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSTOMIA
EP3556382A4 (en) METHOD FOR PREVENTING AND TREATING SKIN FIBROSIS
EP3395341C0 (en) COMPOSITION FOR THE TREATMENT OF NEUROMOTOR DISEASES AND ITS USE
EP3490476A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP3600291A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF SYNUCLEINOPATHIES
IL256249A (en) The vehicle for treating hair loss and increasing its growth